| NCT04729387 | III | Platinum resistant or refractory gBRCA WT high grade serous or endometrioid ovarian cancer | EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer | AZ, AR, FL, IL, MD, MA, NY, OH, SD, TN, TX | View Drugs | View Results |
Alpelisib | PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray | PI3K alpha inhibitor | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04931342 | II | Platinum resistant low-grade serous, low-grade endometrioid, clear cell, mucinous, undifferentiated, malignant Brenner tumors, small cell carcinoma of the ovary-hypercalcemic type or carcinosarcoma | A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | AZ, CA, MN, MO, NY, NC, OK, OR, PA, TX, UT, VA, WA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Cobimetinib | XL518, GDC-0973, Cotellic | MEK1 inhibitor | Approved in Other Cancers | Giredestrant | GDC-9545, selective estrogen receptor downregulator GDC-9545 | ER antagonist (SERD) | Clinical Trials | Inavolisib | RG6114, GDC-0077 | PI3K alpha inhibitor | Clinical Trials | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT05238831 | II | Recurrent ovarian cancer | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT) | OR | View Drugs | |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Alpelisib | PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray | PI3K alpha inhibitor | Approved in Other Cancers | Anastrozole | Arimidex | Aromatase inhibitor | | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Bevacizumab | Avastin, anti-VEGF monoclonal antibody, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain | VEGF antagonist | Approved in Ovarian Cancer | Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cobimetinib | XL518, GDC-0973, Cotellic | MEK1 inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Eribulin | B1939 mesylate, E7389, ER-086526, Halaven, halichrondrin B analog | Microtubule destabilizer/mitotic inhibitor | Approved in Other Cancers | Fulvestrant | Faslodex, ICI 182,780, ZD9238 | ER antagonist (SERD) | Approved in Other Cancers | Irinotecan | Campothecin-11, Campto, Camptosar | Topoisomerase I inhibitor | NCCN Guidelines for Ovarian Cancer | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Approved in Other Cancers | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers | Vemurafenib | RO5185426, PLX4032, Zelboraf | BRAF kinase inhibitor | Approved in Other Cancers | Vinorelbine | Biovelbin, Eunades, Navelbine, Navelbine ditartrate, NVB, Vinorelbine tartrate, VNB, Vinorelbine ditartrate | Microtubule destabilizer/mitotic inhibitor | | Vismodegib | Hedgehog antagonist GDC-0449, Erivedge, GDC-0449 | Smoothened antagonist | Approved in Other Cancers |
|
|
| NCT05295589 | II | Platinum resistant or refractory high grade serous or endometrioid ovarian cancer or platinum resistant or refractory BRCA MUT ovarian cancer that must have had prior bevacizumab and must have progressed on prior PARP inhibitor therapy (≤ 2 prior therapies for platinum resistant disease) | A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) and PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients With Recurrent Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy | Contact research study staff | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03586661 | Ib | Recurrent high grade serous ovarian cancer or BRCA MUT ovarian cancer that must have progressed after PARP inhibitor maintenance therapy (in expansion) | A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03842228 | Ib | Advanced solid tumors with alterations in ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, PIK3CA (E542, E545 or H1047), POLD1, PPP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L or XRCC2 (in expansion) | A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors | CO, MA, TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04586335 | I | Advanced solid tumors with mutations in DDR genes or PIK3CA, with no prior PARP inhibitor (inc ovarian expansion) | Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | TX | View Drugs | View Results |
|
|